Natera (NTRA) Upgraded to “Hold” by Zacks Investment Research

Natera (NASDAQ:NTRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Saturday.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

Get Natera alerts:

Several other equities analysts have also recently commented on NTRA. BidaskClub cut Natera from a “sell” rating to a “strong sell” rating in a report on Friday. ValuEngine raised Natera from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 15th. Finally, Cowen reaffirmed a “buy” rating and issued a $30.00 price target on shares of Natera in a report on Friday, November 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Natera currently has an average rating of “Buy” and an average target price of $28.25.

NASDAQ NTRA opened at $16.48 on Friday. Natera has a twelve month low of $8.60 and a twelve month high of $29.62. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30. The stock has a market cap of $995.30 million, a P/E ratio of -6.87 and a beta of 1.79.

Institutional investors have recently bought and sold shares of the business. Pacer Advisors Inc. acquired a new position in Natera in the 3rd quarter valued at approximately $106,000. Point72 Hong Kong Ltd acquired a new position in Natera in the 3rd quarter valued at approximately $119,000. Quantbot Technologies LP acquired a new position in Natera in the 3rd quarter valued at approximately $135,000. Legal & General Group Plc raised its holdings in Natera by 14.5% in the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its holdings in Natera by 136.8% in the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 3,420 shares in the last quarter. 87.92% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: What is a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com